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Japanese encephalitis (JE) is a vector-borne disease caused by the 
Japanese encephalitis virus (JEV). JEV is transmitted by mosquitoes 
to a wide range of vertebrate hosts, including birds and mammals. 
Domestic animals, especially pigs, are generally implicated as reser-
voirs of the virus, while humans are not part of the natural transmis-
sion cycle and cannot pass the virus to other hosts. Although JEV 
infection is very common in endemic areas (many countries in Asia), 
less than 1% of people affected develop clinical disease, and severe 
disease affects about 1 case per 250 JEV infections. Although rare, 
severe disease can be devastating; among the 30,000-50,000 global 
cases per year, approximately 20-30% of patients die and 30-50% of 
survivors develop significant neurological sequelae. JE is a signifi-
cant public health problem for residents in endemic areas and may 
constitute a substantial risk for travelers to these areas. The epide-
miology of JE and its risk to travelers have changed, and continue 
to evolve. The rapid economic growth of Asian countries has led to a 
surge in both inbound and outbound travel, making Asia the second 
most-visited region in the world after Europe, with 279 million inter-
national travelers in 2015. The top destination is China, followed 
by Thailand, Hong Kong, Malaysia and Japan, and the number of 
travelers is forecast to reach 535 million by 2030 (+ 4.9% per year). 
Because of the lack of treatment and the infeasibility of eliminating 
the vector, vaccination is recognized as the most efficacious means of 
preventing JE. The IC51 vaccine (IXIARO®) is a purified, inactivated, 
whole virus vaccine against JE. It is safe, well tolerated, efficacious 
and can be administered to children, adults and the elderly. The vac-
cination schedule involves administering 2 doses four weeks apart. 
For adults, a rapid schedule (0-7 days) is available, which could 
greatly enhance the feasibility of its use. Healthcare workers should 
inform both short- and long-term travelers of the risk of JE in each 
period of the year and recommend vaccination. Indeed, it has been 
shown that short-term travelers are also at risk, not only in rural envi-
ronments, but also in cities and coastal towns, especially in tourist 
localities where excursions to country areas are organized.
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Summary
Introduction
Japanese encephalitis (JE) is a vector-borne disease 
caused by the Japanese encephalitis virus (JEV), which 
is a single-stranded RNA virus belonging to the genus 
Flavivirus (Flaviviridae family) and is closely related to 
the West Nile encephalitis virus [1].
There are five JEV genotypes in the world, but geno-
type 1 circulates much more than the others [2, 3]. JEV 
is transmitted by mosquitoes to a wide range of verte-
brate hosts, including birds and mammals. With regard 
to human infection, domestic animals, especially pigs, 
are generally implicated as reservoirs of the virus. As 
humans are not part of the natural transmission cycle, 
they cannot pass the virus to other hosts [4].
While JEV infection is very common in endemic areas 
(many countries in Asia), less than 1% of people affected 
develop clinical disease  [2], and severe disease affects 
about 1 case per 250 JEV infections. Although rare, 
severe disease can be devastating; among the 30,000-
50,000 global cases per year, approximately 20-30% of 
patients die and 30-50% of survivors develop significant 
neurological sequelae [5].
JE is a significant public health problem for residents 
in endemic areas and may constitute a substantial risk 
for travelers to endemic areas. Because of the lack of 
treatment and the infeasibility of eliminating the vector, 
vaccination is recognized as the most efficacious means 
of preventing JE [4].
This overview focuses on the epidemiology and clinical 
features of JE and describes the use of the IC51 vaccine 
(IXIARO®) in travel medicine.
Epidemiology of japanese encephalitis
The vector of the JEV is the Culex mosquito, specifically 
Culex tritaeniorhyncus, which lives and breeds in water 
pools and flooded rice fields. This type of mosquito bites 
during night, with two peaks in biting time: a few hours 
after sunset and around midnight [6].
Humans and some kinds of animals, such as cattle or 
horses, are dead-end hosts of JEV, as they cannot de-
velop a sufficient level of viremia to re-infect other 
mosquitoes. Transmission among humans is not possi-
ble, although transfusion-related JEV transmission was 
reported in two immunocompromised lung transplant 
recipients in Hong Kong, resulting in one case of severe 
encephalitis and one case of asymptomatic infection 
with seroconversion [7].
Culex tritaeniorhyncus lives throughout South-East Asia 
and tropical areas. However, its presence also extends 
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to the Middle East and Africa, and has recently been 
reported even in Europe. Within endemic areas, trans-
mission varies according to climatic conditions: in tem-
perate areas of Asia, transmission is seasonal, especially 
during summer and fall; in subtropical and tropical ar-
eas, transmission occurs during the monsoon season, but 
can be prolonged throughout the year [2].
The global incidence of JE is unknown, as the intensity 
and quality of JE surveillance systems and the avail-
ability of diagnostic laboratory testing vary throughout 
the world [8]. JE surveillance was not well established 
until 2012 and a 2011 systematic review of JE disease 
burden  [8] estimated that approximately 68,000 cases 
occurred globally each year, and that only about 10% 
of these cases were reported to the WHO [9]. In 2011, 
Campbell et al.  [8] reported that, owing to the lack of 
efficacious surveillance systems, it was difficult obtain a 
precise estimate of the incidence of JE. Nevertheless, it 
was estimated that 3 billion people living in 24 countries 
in the WHO’s South-East Asian and Western Pacific 
regions are at risk of JE  [8,  3]. The authors estimated 
that about 67,900 cases per year occurred in JE-endemic 
countries, with half of these cases in China alone. They 
also classified countries in terms of their incidence 
(high, medium and low) and the availability of vaccina-
tion (vaccination implemented, vaccination program ex-
panding, and no vaccination) (Figure 1). Although Japan, 
the Republic of Korea and Taiwan are “high-incidence” 
countries, their routine vaccination programs have ena-
bled them to limit JE incidence to 0.003 per 100,000 in 
the overall population. Vaccination began in Japan in 
1954, in Taiwan in 1968, and in Korea in 1970. In Japan, 
however, following the withdrawal of the recommenda-
tion in 2005, vaccination coverage declined; although 
the recommendation was reinstated in 2009, coverage 
remains low. By contrast, China, which is also a high-in-
cidence country, does not have a quality vaccination pro-
gram (vaccination was implemented from 1981 to 2007, 
but non-uniformly in children; a routine vaccination pro-
gram was started in 2008). Consequently, the incidence 
of JE is 3.3 overall, 12.7 in children aged 0-14 years and 
1.0 in subjects aged > 15 years. Some countries where 
JE incidence is high do not implement any, or are only 
now developing, vaccination programs: Cambodia, In-
donesia, Laos, Malaysia, Myanmar, Philippines and East 
Timor. Moreover, countries such as India and Nepal are 
improving their routine vaccination programs.
Medium-incidence countries (such as Indonesia and 
Papua New Guinea) have a total incidence rate of 1.7 per 
100,000, while those with low incidence have a rate of 
1.0 per 100,000 (Fig. 1).
Annual incidence varies by age-group, with children 
being the most affected [8]. Most adults are immune to 
infection, as natural infection with JEV (or other Flavi-
viruses that share antigens inducing cross-protection) is 
probably able to confer lifelong immunity. This explains 
why children are the most susceptible subjects [3, 4]. It is 
noteworthy that, where childhood vaccination programs 
are implemented, there is a shift to a greater proportion 
of cases in other unvaccinated age-groups [3]. 
In 2016, 22 of 24 (92%) countries at risk of JE ran sur-
veillance systems, compared with 75% in 2012; some 
of these systems are national, some are sub-national and 
others use sentinel surveillance. In 12 of the 24 countries 
(50%), an immunization program was in place in 2016. 
Some of these immunization programs are national, oth-
ers are sub-national in all risk areas, and several are sub-
national but do not include all risk areas [9].
Recently, several factors have changed the geographical 
distribution of JE. First of all, international travel, es-
pecially for reasons of work, has increased. Indeed, the 
growth of US-based multinational corporations in Asia 
in the last twenty years has led to a significant rise in 
the number of business travelers. The business travelers 
frequently have to spend short or long periods in Asia, 
where they acquire the same risk of JE as the local popu-
lation. Furthermore, changes have taken place in agricul-
ture; in many areas of Asia, both rice production and pig 
farming have been intensified, which could lead to the 
development of a high risk of JE even in suburban areas, 
which were not at risk some years ago. The epidemiol-
ogy of JE is also influenced by ecological and climatic 
factors. The appearance of JEV in Tibet (a cold, high-
altitude region) and the emergence of two new serotypes 
of JEV in Australia provide confirmation that the spread 
of JEV is unpredictable. Moreover, global warming may 
lead to a change in the peak and duration of JEV trans-
mission [5].
Clinical features and treatment
Most infections are asymptomatic or cause non-specific 
febrile symptoms [4]. Incubation time ranges from 5 to 
15 days; the non-specific febrile illness that frequently 
constitutes the clinical presentation of JE may be the on-
ly manifestation in some patients [10]. Other symptoms 
can occur: coryza, diarrhea and rigor, followed by the 
onset of altered consciousness and seizures (convulsions 
occur in 75% of children) [3] or vomiting after several 
days [11]. When the disease is severe, affecting the cen-
tral nervous system, the clinical features are mental sta-
tus changes, focal neurological deficits, weakness and, 
after a few days, even movement disorders. Moreover, 
classical symptoms associated with severe JE are Par-
kinsonian syndrome, with mask-like face, tremor, cog-
wheel rigidity and choreoathetoid movements. Rarely, 
the clinical presentation can include acute facial paraly-
ses (similar to poliomyelitis paralyses) [2]. Blood tests 
reveal neutrophilia, hyponatremia, elevated liver en-
zymes and cerebrospinal fluid (CSF) pleocytosis, with 
lymphocytic predominance [12, 2]. JE is most common-
ly diagnosed by testing for JEV IgM in the CSF, which 
is reliably positive if the CSF sample is taken at least one 
week into illness [13]. Other laboratory tests are molecu-
lar methods [14].
The treatment of JE usually consists of supportive care, 
as there are no specific antiviral therapies. The case fatal-
ity rate is high, and it is estimated that, in endemic areas, 
approximately one third of patients admitted to hospital 
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die [11]. JE-related deaths are due to raised intracranial 
pressure, hypoglycemia and seizures  [2, 3]. JE disease 
also causes serious brain damage in about 25-50% of 
survivors, the highest rate of sequelae being reported in 
children [3, 15]. Moreover, in pregnant women, the in-
fection can cause harm to the fetus.
Even though JE is rare, it is potentially a severe life-
changing illness and requires prevention. Vaccination is 
the cornerstone of JE control.
International travelers
The epidemiology of JE and its risk to travelers have 
changed, and continue to evolve. Estimates of JE inci-
dence among Western travelers to tropical and subtropi-
cal destinations show that the usual itineraries followed 
by tourists or businesspeople are considered at low risk 
of infection (< 1 per 1,000,000 travelers per month) [16]. 
The risk of travelers contracting JE varies according to 
their travel itinerary. The overall risk of about 1/400,000 
visits [17] may, however, increase for certain high-risk 
groups, such as those who stay for long periods in rural 
areas, approaching the risk of 1/50,000 per week seen 
in the local population [18, 19]. From 1973 to 2008, 55 
cases were reported in travelers, most of whom were 
“high-risk travelers” who had spent a month or more 
in endemic regions (especially rural areas) and had ac-
quired the same risk of JE as the local population. The 
case-fatality rate was 18% and 24 survivors developed 
sequelae. Even though long stays have always been con-
sidered a risk factor, the authors found that 13 of the 55 
cases occurred in travelers who had stayed for less than 
1 month: 10 for 2-4 weeks and 3 for 10-12 days trip [20]. 
This demonstrates that short-term travelers also have a 
JE disease risk.
Kollaritsch H. et al. [21] also reported JE cases in travel-
ers, and from 1973 to 2015 the Centers for Disease Con-
trol and Prevention reported 79 cases among travelers 
or expatriates from non-endemic countries  [2]. Some 
of these cases could have been avoided if travelers had 
been vaccinated in accordance with current recommen-
dations.
More recently, a fatal case of JEV infection following 
short-term travel to Thailand was reported. In this case, 
JE viral RNA was detected in urine and whole blood 26 
and 28 days, respectively, after the onset of symptoms. 
Furthermore, live virus was isolated from a urine speci-
men taken on day 14. This suggests that testing whole 
blood and urine could offer additional diagnostic infor-
mation in certain situations [22].
It is well known that most cases of JE are asymptomatic. 
Consequently, a large number of infections may go un-
recognized. Moreover, in the near future, JE could be-
come a major public health issue even in non-endemic 
countries, as a result of cultural, economic and climatic 
changes [16].
Travel is changing; the increased speed and availability 
of transport (especially by air) encourages inter-regional 
and international tourism and business trips. In terms of 
population, Asia and the Pacific are the world’s largest 
regions, with 4.1 billion inhabitants in 2015, about 56% 
of the world’s total population [23]. The rapid econom-
ic growth of Asian countries has led to a surge in both 
inbound and outbound travel, making Asia the second 
most-visited region in the world after Europe, with 279 
million international travelers in 2015. The top destina-
tion is China, followed by Thailand, Hong Kong, Ma-
laysia and Japan, and the number of travelers is forecast 
to reach 535 million by 2030 (+4.9% per year). Accord-
ing to the United Nations Word Tourism Organization 
(UNWTO), this unprecedented growth in travel is the 
consequence of the Asian economic boom. Further, 
Fig. 1. Incidence of JE and vaccination policies in Asian countries [8].
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a large and growing number of “free and independent 
travelers”, identifiable as a “consumer class”, especial-
ly young Asian travelers aged 15-34 years (“millenni-
als”), use online travel agencies and mobile technology. 
Their destinations are often secondary and tertiary cities, 
which could be potentially at risk of JE  [24]. Further-
more, if they travel alone or simply organize their travel 
on their own, they are unlikely to be informed about JE, 
its symptoms and prevention. These changes in travel 
habits should prompt different information strategies, 
e.g. the use of social media, and collaboration between 
public health organizations and the most widely used 
travel websites.
Prevention of japanese encephalitis
Travelers to JE-endemic areas can reduce their exposure 
to vectors by adopting personal protective measures: 
using mosquito-repellent agents, wearing appropriate 
clothing, avoiding outdoor activities in the evening, us-
ing permethrin-impregnated mosquito nets and staying 
in rooms with air conditioning. In combination with 
these protective measures, vaccination against JEV in-
fection can provide travelers with safe and effective pro-
tection [21, 25].
Different vaccines against JE have been available since 
the 1950s  [14]. First-generation JE vaccines were of 
various types; mouse brain-derived inactivated vaccines, 
inactivated vaccines cultivated on primary hamster kid-
ney cells, live attenuated vaccines based on strain SA 
14-14-2 and cultivated on primary hamster kidney cells 
have been widely used for the past few decades [26]. Al-
though mouse brain-derived vaccine was used for sev-
eral decades in the US and Europe, its production has 
been discontinued, owing to its unsatisfactory safety 
profile  [24, 25]. A formalin-inactivated vaccine devel-
oped in China in 1968 was cultivated in Vero cells and 
used the P-3 strain; this was widely used and displayed 
a good safety and effectiveness profile [25, 26]. A live-
attenuated SA14-14-2 vaccine authorized in 1988 is 
currently used in Nepal, India, Sri Lanka, Thailand and 
South Korea, and has proved to be a valid tool in terms 
of effectiveness and safety [25].
More interestingly, second-generation JE vaccines are 
available, which use a lower dosage scheme and exhibit 
a better safety profile; these constitute a noteworthy op-
tion for the protection of residents of endemic areas and 
travelers. They are the IC51 Japanese encephalitis vac-
cine (IXIARO®) and the chimeric Japanese encephalitis 
vaccine.
Overall, vaccination has dramatically reduced the num-
ber of JE cases in several Asian countries [8]. However, 
as the virus is maintained in animal reservoirs, non-im-
mune travelers remain at risk of infection in all endemic 
areas of South-East Asia.
Development of the IC51 vaccine (IXIARO®)
The IC51 vaccine (IXIARO®) is a purified, inactivated, 
whole virus vaccine against JE. Developed at the Walter 
Reed Army Institute of Research, it is based on an SA14-
14-2 virus strain cultivated in Vero cells and formulated 
with 0.1% aluminum hydroxide [27]. Each 0.5 ml dose 
of IC51 vaccine comes in a ready-to-use liquid format 
that contains 0.1% aluminum hydroxide as an adjuvant; 
it does not contain stabilizers such as porcine gelatin or 
preservatives such as thimerosal.
Several clinical trials have positively evaluated the im-
munogenicity and safety of the IC51 vaccine. The first 
studies were carried out to evaluate its immunogenic-
ity and safety in comparison with placebo or mouse-
brain JE vaccines. The encouraging results, in terms of 
immune response and low reactogenicity, of a phase I 
study [21] that evaluated different doses of vaccine (0.4 
micrograms and 2.0 micrograms following a 0 and 28, 
or a 0, 7 and 28 schedule) in 25 adult subjects prompted 
subsequent studies.
Lyons et al. reported the results of a phase II study, con-
ducted from 2001 to 2003, which enrolled a total of 94 
subjects. The vaccine was administered in two or three 
intramuscular doses (6.0 or 12.0 micrograms each) with 
observation over 8 weeks. No serious adverse reactions 
were observed. The vaccine was well tolerated and con-
ferred high seroconversion rates [day 56 (primary end-
point): 95-100%] and induced persisting immune re-
sponses up to 2 years after vaccination [28].
Subsequent phase III trials were conducted. In a multi-
center, observer-blinded, randomized controlled phase 
III trial, 867 adult volunteers received either two intra-
muscular doses the JEV test vaccine (on days 0 and 28; 
n = 430) or the licensed vaccine (JE-VAX®) subcutane-
ously according to its recommended three-dose sched-
ule (on days 0.7, and 28; n = 437). The safety profile 
of the test vaccine was good, and its local tolerability 
profile was more favorable than that of the licensed vac-
cine. The frequency of adverse events was similar in 
both treatment groups and adverse events were gener-
ally mild. The seroconversion rate of the test vaccine 
was 98%, compared with 95% for the licensed vaccine, 
on day 56. The geometric mean titer in recipients of the 
test vaccine was 244, compared with 102 for the licensed 
vaccine [ratio 2.3 (95% CI 1.967-2.75)] [29].
Later, the same research group published the results of 
a randomized multi-center phase III trial. Healthy sub-
jects were randomized to receive 2 doses of IC51 vac-
cine (n = 2012) or placebo (n = 663) four weeks apart. 
Adverse events were documented over a period of 2 
months. The rate of severe events was similar in both the 
IC51 group (0.5%) and the placebo group (0.9%) dem-
onstrating a good safety profile of IC51 vaccine. These 
data, together with the immunogenicity data from the 
previous phase III clinical trial, were the basis for the 
authorization of the IC51 vaccine [29, 30].
In another study, adult subjects were followed up in or-
der to compare the immunogenicity of the IC51 vaccine 
and the vaccine JE-VAX®. At 6 months, immunogenic-
ity was higher with the IC51 vaccine (seroconversion 
rate [SCR]: 95%; geometric mean titer [GMT]: 84) than 
with JE-VAX® (SCR: 74%; GMT: 34). With regard to 
IC51, the SCR at 12 months was 83% and the GMT re-
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mained above the protective titer of 1:10. This phase III 
follow-up study confirmed that the immune response 
following IC51 vaccination was more robust than the 
immune response following JE-VAX® [31].
The standard administration of IC51 is of 2 doses of 6 
micrograms 28 days apart. However, one study inves-
tigated the immunogenicity of a single-shot, high-dose 
regimen (1 x 12 micrograms) in comparison with the 
2-injection, standard regimen. The single-shot, high-
dose regimen resulted in about 60% SCR 10 days after 
administration, but did not reach the almost 100% SCR 
achieved by the 2-dose standard administration on day 
35. The standard regimen conferred essentially 100% se-
roconversion 7 days after the second injection [32].
On December 18, 2008, the European Committee for 
Medicinal Products for Human Use (CHMP) recom-
mended granting marketing authorization for the IC51 
vaccine (IXIARO®) in the 27 countries of the European 
Union and in Norway and Iceland. In the US, IXIARO® 
was authorized and recommended for use in persons 
aged ≥ 17 years in 2009  [33]. The product is also ap-
proved and available in Canada, Switzerland and Aus-
tralia.
In the first 12 months after licensing, the safety pro-
file of IXIARO® was reviewed on the basis of clinical 
trial results and post-marketing safety data. The clinical 
safety profile was derived from a pooled analysis that 
included safety data from 10 phase III trials carried out 
in 4,043 subjects who had received at least one dose of 
IXIARO® and were followed up for 3 years after the pri-
mary immunization. The local and systemic tolerability 
of IXIARO® was similar to that seen in the previous 
evaluation at the time of licensure of the vaccine. On 
post-marketing surveillance, no serious allergic reac-
tions were observed. This comprehensive safety review 
confirmed the good safety profile of IXIARO® in clini-
cal and post-marketing use [34].
A phase III study investigated the immunogenicity and 
safety of IC51 and HAVRIX1440 (hepatitis A vaccine) 
when administered alone or concomitantly to healthy 
subjects. The immune response elicited by single admin-
istration was compared with that of concomitant vacci-
nation in terms of GMT and SCR on days 28 and 56. The 
results indicated that the immunogenicity of the two vac-
cines was comparable, whether they were administered 
together or separately. On the basis of these data, the 
authors affirmed that travelers to endemic regions could 
receive both vaccines concomitantly [35].
Eder S. et al. assessed the effect of a booster dose on 
neutralizing JE antibody titers up to 12 months after 
boosting. The booster dose of IXIARO® was adminis-
tered 15 months after the primary immunization to 198 
subjects who had previously been immunized in a ran-
domized trial [36]. Neutralizing antibody titers were as-
sessed by means of the plaque-reduction neutralization 
test (PRNT). Prior to the booster dose, 69.2% (137/198) 
of subjects had PRNT50 titers  ≥  1:10. One month af-
ter the booster, the rate of subjects with PRNT50 ≥ 1:10 
(recognized as a protective titer) had increased to 100%. 
The evaluation of PRNT50 showed a high rate (98.5%) 
at 6 and 12 months. GMTs were 22.5 before the booster 
and 900, 487 and 361 at 1, 6 and 12 months, respec-
tively, after the booster. The booster dose of IXIARO® 
15 months after primary immunization proved highly 
immunogenic; GMTs were >  5-fold higher than those 
seen immediately after primary immunization, and re-
mained at high levels for at least 12 months after the 
booster [37].
IXIARO® in children
In 2009, phase III studies to evaluate the immunogenic-
ity and safety of administering the IC51 vaccine to chil-
dren began. A study involving 60 healthy Indian children 
aged between 1 and 3 years evaluated the immunogenic-
ity and safety of 3 and 6 micrograms of IXIARO® in 
comparison with the licensed vaccine JenceVac. Immu-
nogenicity was assessed by measuring antibodies at the 
baseline and 28 days after the first and second admin-
istrations. On day 56, SCRs in the 3- and 6-microgram 
IXIARO® groups and the JenceVac group were 95.7%, 
95.2% and 90.9%, respectively, and GMTs were 201, 
218 and 230, respectively. Local and systemic toler-
ability was registered in a diary 7 days post-vaccination. 
No apparent difference was seen in the safety profiles of 
the two vaccines. These first immunogenicity and safety 
data in children supported the use of a 3-microgram dose 
in children under 3 years of age [38].
A very recent uncontrolled, open-label, phase III trial 
was carried out in order to assess the safety and immu-
nogenicity of IXIARO® in a population of previously 
JEV-unexposed travelers to JE-endemic regions  [39]. 
The vaccine was administered to 100 travelers aged ≥ 2 
months to <  18 years. Solicited adverse events were 
observed for 7 days after each injection, and unsolic-
ited adverse events for a total of 7 months. Further-
more, JE neutralizing antibodies were investigated in 
64 subjects. Two different vaccine doses were studied: 
0.25 and 0.50 ml IXIARO®. The most common solic-
ited local adverse events were redness, induration and 
tenderness with 0.25 ml IXIARO®, and tenderness and 
pain with 0.5 ml IXIARO®. Common solicited systemic 
adverse events were diarrhea and loss of appetite with 
0.25 ml IXIARO® and muscle pain and excessive fatigue 
with 0.5 ml IXIARO®. In total, up to day 56, adverse 
events were reported by 83.3% of subjects who had re-
ceived the 0.25 ml dose and 76.1% of those vaccinated 
with the 0.5 ml dose. All subjects had developed protec-
tive levels of JE neutralizing antibodies by day 56, and 
91.2% retained protective titers at month 7. IXIARO® 
was generally well tolerated in children, with an overall 
safety profile similar to that seen in adults. Moreover, it 
was highly immunogenic in both dose-groups.
Another recent study  [40] monitored the safety profile 
of IXIARO® in a pediatric population of 1869 children 
aged between 2 months and 17 years, who were recruit-
ed and randomized in an age-stratified manner to receive 
IXIARO® or one of the control vaccines: Prevenar® and 
HAVRIX®. Adverse events, serious adverse events and 
medically attended adverse events were assessed up to 
day 56 and month 7 after the first dose. This study showed 
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that incidences of adverse events, serious adverse events 
or medically attended adverse events did not differ sig-
nificantly between the groups. Adverse events were 
most frequent in children < 1 year of age and decreased 
with age. Adverse events of special interest, such as 
hypersensitivity/allergy or neurological disorders up to 
day 56, were reported in 4.6% (IXIARO®) versus 6.3% 
(Prevenar®) in the ≥ 2 months to < 1 year age-group and 
in 3.4% (IXIARO®) versus 3.3% (HAVRIX®) in the ≥ 1 
to < 18 years age-group. Fever, the most frequent sys-
temic reaction, was observed in 23.7% of infants and 
3.8% of adolescents, and decreased with age. The au-
thors concluded that the safety profile of IXIARO® was 
comparable to that of the control vaccines.
Another study also evaluated the immunogenicity of 
IXIARO®. Age-stratified cohorts of children between 2 
months and 17 years of age received 2 doses of IXIARO® 
administered 28 days apart [< 3 years, 0.25 mL (half adult 
dose); ≥ 3 years, 0.5 mL (full adult dose)]. The endpoints 
were seroconversion rate, 4-fold increase in JE neutral-
izing antibody titer and geometric mean titer assessed 56 
days and 7 months after the first administration. A total of 
496 subjects were enrolled and the immune response to 
JE virus at both time-points was also analyzed according 
to pre-vaccination JE virus and dengue virus serostatus. 
On day 56, seroconversion had been obtained in ≥ 99.2% 
of subjects, 4-fold increases in titer were reported in 77.4-
100% in various age-groups, and geometric mean titers 
ranged from 176 to 687, with younger children displaying 
the greatest immune response. At month 7, seroconver-
sion was maintained in 85.5-100% of subjects. Pre-ex-
isting JE virus immunity did not impact on the immune 
response at day 56; however, it yielded better persistence 
of protective antibody titers at month 7 [41]. The above 
findings revealed that IXIARO® was highly immunogenic 
in the pediatric population at both doses tested, eliciting 
protective antibody titers by day 56 in > 99% of subjects 
who received the age-appropriate dose.
In May 2013, the Food and Drug Administration (FDA) 
licensed IXIARO® for use in children aged 2 months 
through 16 years [42], and in the same year the vaccine 
was also indicated for children by the European Medi-
cines Agency (EMA) [43].
IXIARO® in the elderly
The safety and immunogenicity of IXIARO® were also 
evaluated in a clinical trial involving elderly subjects. 
An open-label, single-arm, multi-center study was con-
ducted in 200 healthy subjects aged 64-83 years, includ-
ing those with adequately controlled chronic conditions, 
who received two doses of IXIARO® 28 days apart. 
Antibody levels were tested 42 days after the second 
dose. Systemic and local adverse events were moni-
tored for 7 days after each dose, and unsolicited adverse 
events were recorded up to day 70 and subsequently at 
month 7. Although 19% of subjects had serious or medi-
cally attended adverse events up to day 70 (primary end-
point), none of these was associated with the vaccine. 
Solicited local adverse events were reported by 33.5% 
of participants, the most common being local tender-
ness; solicited systemic adverse events were reported 
by 27% of participants, the most common being head-
ache. A seroprotection rate of 65%, with a GMT of 37, 
was found. Subjects who had received a tick-borne en-
cephalitis (TBE) vaccine in the previous 5 years had an 
SCR of 90% and GMT of 65. The authors concluded 
that IXIARO® was generally well tolerated in the el-
derly, and that its safety profile was largely comparable 
to that seen in younger adults. While SCR and GMT 
were lower than in younger adults, SCR was in the 
range reported in the elderly for other vaccines, such as 
TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), 
and influenza vaccines. Another aspect to be taken into 
account was the duration of protection, which is uncer-
tain in the elderly. The authors therefore suggested that 
a booster dose (third dose) should be considered before 
any further exposure to JEV [44].
Dosage, administration and schedule  
of IXIARO®
IXIARO® is injected into a muscle, preferably the 
shoulder muscle, or, in young children, into the thigh 
muscle. In adults, including those aged over 65 years, 
and children aged three years and older, a full dose of 
IXIARO® (0.5 ml) should be administered, and an ad-
ditional 0.5 ml dose should be given four weeks later. In 
adults aged 18-65 years, a rapid vaccination course may 
also be implemented, in which the second dose is given 
seven days after the first. In children aged between two 
months and three years, half the adult dose of IXIARO® 
(0.25  ml) should be given, and an additional 0.25 ml 
dose should be given four weeks later. It is recommended 
that individuals who receive the first dose of IXIARO® 
should receive both doses, and that the second dose be 
given at least one week before potential exposure to the 
virus. In adults, the second dose can be given up to 11 
months after the first. Adults aged 18-65 years who are 
likely to be exposed to the JEV again, or who are at con-
tinuous risk of the disease, should receive a booster dose 
of IXIARO® one to two years later and a second booster 
dose 10 years after the first booster. Children and adoles-
cents may also receive a booster dose one to two years 
after the initial vaccination. A booster dose should also 
be considered for adults aged over 65 years before any 
further exposure to JEV. IXIARO® can be injected under 
the skin in people who have a bleeding disorder, such as 
low blood platelet counts or hemophilia [43].
A randomized, observer-blind, phase 3 study evaluated 
the immunogenicity of IXIARO® administered according 
to a rapid schedule [43]. Two cohorts were recruited: 217 
subjects aged 18-65 years received IXIARO® together 
with rabies vaccine in a rapid immunization schedule (0-
7 days); 56 subjects received IXIARO® according to the 
common immunization schedule (0-28 days). Serocon-
version was similar in both cohorts and seroconversion 
rates and antibody titers remained high in both groups 
up to 12 months after immunization. With the rapid 
schedule, seroconversion rates on days 14 and 21 and 
after one year were 99%, 100% and 94%, respectively; 
at the same time-points, GMT values were 715, 1255 
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and 117, respectively. A third dose (first booster dose) 
was given within the second year (12-24 months) after 
the primary vaccination course. Long-term seroprotec-
tion data following a first booster dose suggested that a 
second booster should be given 10 years after the first, 
prior to potential exposure to JEV.
Subsequently, antibody persistence after booster immu-
nization in adults was assessed in an uncontrolled, open-
label extension, in which 67 subjects were followed up 
to determine JEV neutralizing antibody titers approxi-
mately 6 years after a booster dose. In 96% of subjects 
(64/67), protective antibody levels (PRNT50  ≥  1:10) 
persisted, with a GMT of 148 (95% CI:107-207). Math-
ematical modeling was applied to evaluate the average 
duration of protection. On the basis of this model, it was 
estimated that the average duration of protection would 
be 14 years and that 75% of vaccinees would retain pro-
tective antibody levels (PRNT50 ≥ 1:10) for 10 years. A 
second booster should therefore be given 10 years after 
the first, prior to potential exposure to JEV [43]. Some 
authors have speculated that the protection conferred by 
the booster dose could last for a lifetime.
Conclusions
JE is the main cause of viral encephalitis in many Asian 
countries, and causes significant morbidity and mortal-
ity in autochthonous populations. Survivors often suf-
fer permanent severe neurological sequelae that require 
lifelong support and care. The burden of the disease is 
heavy not only in terms of its clinical impact, but also on 
account of its socio-economic consequences in endemic 
areas. JE epidemics have also been documented, such as 
the outbreaks in India, which caused about 400 cases in 
2014 and 1700 deaths in 2005 [45, 46].
As mentioned above, JE virus transmission is seasonal. 
However, climate changes and increasingly extreme 
weather conditions could lengthen the infective period 
of the JE virus. Moreover, the areas affected by JE have 
gradually expanded; indeed, growing numbers of JE 
cases have been observed further north in Asia, owing 
to the rise in global temperatures. For example, cases 
have spread to Nepal from Northern India, and the dis-
ease has now become widespread in hill and mountain 
districts  [47]. JE cases have also been associated with 
increasingly frequent floods in China [48].
Travelers to endemic areas are exposed to the risk of 
acquiring a serious JE infection, and the rise in interna-
tional travel to Southeast Asia has exacerbated this risk. 
Published recommendations for travelers underscore 
the importance of considering the travel destination, 
the high morbidity and mortality rates of JE, the lack 
of available treatment, travel-related factors (itinerary, 
duration, season and activity) and the benefits of JE vac-
cination [26, 33]. With regard to the risk of JE infection, 
the activity of the traveler is more significant than the 
length of the stay. Indeed, activities such as camping, 
trekking, biking, fishing and hunting increase the risk 
of exposure to the mosquitoes that transmit the JE virus. 
The fact that holiday-makers are now more inclined to 
engage in outdoor activities and to stay in unconvention-
al tourist lodgings may have contributed to the recent 
increase in cases among travelers [49].
Travelers should be aware of the risk of contracting JE 
and how it can be prevented by vaccination, as this dis-
ease can have devastating effects. IXIARO® can be ad-
ministered to children, adults and the elderly. It is safe, 
well tolerated and efficacious. The vaccination schedule 
involves 2 administering doses four weeks apart. For 
adults, a rapid schedule (0-7 days) is available, which 
could greatly enhance the feasibility of its use.
Healthcare workers should inform both short- and long-
term travelers of the risk of JE in each period of the year 
and recommend vaccination. Indeed, it has been shown 
that short-term travelers are also at risk, not only in rural 
environments, but also in cities and coastal towns, espe-
cially in tourist localities where excursions to country 
areas are organized. In rural areas, the risk is linked to 
potential contact with poultry.
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